Q4 2024 EPS Estimates for Medpace Holdings, Inc. (NASDAQ:MEDP) Lowered by William Blair

Medpace Holdings, Inc. (NASDAQ:MEDP) – Equities research analysts at William Blair lowered their Q4 2024 EPS estimates for Medpace in a report released on Wednesday, July 24th. William Blair analyst M. Smock now anticipates that the company will earn $2.86 per share for the quarter, down from their previous forecast of $2.88. William Blair has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.59 per share. William Blair also issued estimates for Medpace’s Q3 2025 earnings at $3.23 EPS, Q4 2025 earnings at $3.40 EPS and FY2025 earnings at $13.14 EPS.

A number of other equities analysts have also weighed in on MEDP. Guggenheim cut their price objective on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research report on Wednesday. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and lifted their price target for the company from $340.00 to $450.00 in a research report on Tuesday, April 23rd. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday. TD Cowen lowered their price target on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Mizuho assumed coverage on Medpace in a research report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $424.14.

Medpace Stock Performance

Shares of MEDP stock opened at $380.50 on Friday. Medpace has a 1 year low of $227.21 and a 1 year high of $459.77. The stock has a market cap of $11.80 billion, a PE ratio of 38.79, a P/E/G ratio of 1.84 and a beta of 1.36. The stock has a fifty day moving average price of $404.55 and a 200 day moving average price of $381.65.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.54 by $0.21. The firm had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The firm’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.93 earnings per share.

Hedge Funds Weigh In On Medpace

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Medpace by 5.9% in the fourth quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock valued at $783,626,000 after purchasing an additional 142,591 shares in the last quarter. Riverbridge Partners LLC grew its position in shares of Medpace by 7.1% in the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock valued at $199,975,000 after acquiring an additional 43,197 shares during the period. TD Asset Management Inc increased its holdings in shares of Medpace by 22.9% during the 1st quarter. TD Asset Management Inc now owns 574,149 shares of the company’s stock worth $232,042,000 after acquiring an additional 107,108 shares during the last quarter. Epoch Investment Partners Inc. lifted its stake in shares of Medpace by 15.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 406,446 shares of the company’s stock worth $164,265,000 after buying an additional 53,983 shares during the last quarter. Finally, Bessemer Group Inc. boosted its holdings in shares of Medpace by 1.6% during the first quarter. Bessemer Group Inc. now owns 394,834 shares of the company’s stock worth $159,572,000 after acquiring an additional 6,137 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 15,102 shares of the company’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the sale, the chief executive officer now owns 791,541 shares in the company, valued at approximately $317,162,563.29. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the sale, the chief executive officer now directly owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO August J. Troendle sold 5,695 shares of Medpace stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total value of $2,252,315.55. Following the sale, the chief executive officer now directly owns 654,656 shares in the company, valued at $258,909,901.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,621 shares of company stock valued at $11,816,852. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.